Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
NVAX Stock Chart & Stats
$7.05
-$1.22(-11.32%)
At close: 4:00 PM EST
$7.05
-$1.22(-11.32%)
Day’s Range― - ―
52-Week Range$5.01 - $11.55
Previous CloseN/A
Volume4.15M
Average Volume (3M)4.26M
Market Cap
$1.13B
Enterprise Value$885.03M
Total Cash (Recent Filing)$762.89M
Total Debt (Recent Filing)$251.14M
Price to Earnings (P/E)3.9
Beta1.80
Next Earnings
Mar 04, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding162,499,000
10 Day Avg. Volume4,292,490
30 Day Avg. Volume4,264,789
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-1.96
Price to Sales (P/S)1.79
P/FCF Ratio-12.20
Enterprise Value/Market Cap0.78
Enterprise Value/Revenue0.83
Enterprise Value/Gross Profit0.90
Enterprise Value/Ebitda2.16
Forecast
1Y Price Target
$11.25Price Target Upside59.57% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)2.16
Revenue Forecast (FY)$1.06B
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company reported cash and cash equivalents of $774M at the end of 3Q25, which is believed to be sufficient to fund operations into 2H27.
Revenue PerformanceNovavax reported total revenues of $70.4M, compared to consensus estimated revenue of $42M.
Strategic PartnershipsThe agreement to transfer a Maryland facility to AstraZeneca is expected to bring $60M in cash, aiding Novavax in focusing on R&D and license agreements.
Bears Say
Commercialization DifficultiesThere is a difficult road ahead for Nuvaxovid, as commercialization efforts may take years to mature.
Market Share DeclineIn the 2025-26 vaccination season, Nuvaxovid had an average ~0.7% share from Week 1 to Week 8, representing a meaningful decline in market share.
Vaccine Uptake ChallengesThe ACIP committee's focus on clinical/shared decision making and informed consent may pose additional barriers to vaccine uptake.
Novavax News
NVAX FAQ
What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was $5.01 and its highest was $11.55 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is $1.13B.
When is Novavax’s upcoming earnings report date?
Novavax’s upcoming earnings report date is Mar 04, 2026 which is in 94 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Nov 06, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$1.196 by -$0.054.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -0.49.
How many shares outstanding does Novavax have?
Novavax has 162,499,000 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -$1.25 in its last earnings report, missing expectations of -$1.196. Following the earnings report the stock price went down -1.3%.
Which hedge fund is a major shareholder of Novavax?
Currently, no hedge funds are holding shares in NVAX
Novavax Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$11.25 (59.57% Upside)
$11.25 (59.57% Upside)
Blogger Sentiment
Bullish
NVAX Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 979.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.9%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-31.10%
Trailing 12-Months
Company Description
Novavax
Novavax, Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. The company operates primarily in the biotechnology sector and is renowned for its research and development efforts in vaccine technology, particularly for respiratory viruses, including COVID-19. Novavax's core products include its NVX-CoV2373 vaccine candidate for COVID-19, which utilizes recombinant nanoparticle technology, as well as other vaccine candidates for diseases such as influenza and RSV (respiratory syncytial virus).
NVAX Company Deck
NVAX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in strategic partnerships, cost reduction efforts, and financial improvements. However, there were notable challenges, including decreased product sales and a considerable net loss. The positive aspects slightly outweigh the negative, indicating a cautiously optimistic outlook.View all NVAX earnings summariesNVAX Stock 12 Month Forecast
Average Price Target
$11.25
▲(59.57% Upside)
Technical Analysis
Ownership Overview
0.40% Insiders
12.65% Mutual Funds
13.86% Other Institutional Investors
56.54% Public Companies and Individual Investors